Brussels, 14 July 2026

Check against delivery

Dear Ms Jerkovic, dear honourable members, thank you for the invitation today and for this opportunity to report on EMA’s activities. 

Many of you know that it’s my last annual exchange with this committee, because my mandate will end in April, and I am very grateful to the Committee for the great collaboration over the past years.

Today, I am going to look back at some key highlights from our 2025 report, I will update you on some preparations for our new pharmaceutical framework, I will touch on our work on competitiveness and also on women’s health, and then finally I want to share a few personal reflections and important achievements from the past six years.

2025 highlights

Let’s start with the highlights from 2025.

EMA delivered 104 positive recommendations for new medicines for human use, and many of these addressed unmet medical needs. 

Some notable approvals include a medicine to treat early Alzheimer’s, a medicine…